Core Insights - The Nanjing Drum Tower Hospital has launched a Clinical Medicine Research Institute aimed at addressing public health needs through original research and rapid results transformation [1][2] Group 1: Platform Development - The Clinical Medicine Research Institute is a foundational platform for supporting high-quality development in the hospital, focusing on original research based on clinical needs and establishing a closed-loop system for problem-solving and results application [1][2] - The research institute includes various facilities such as a talent apartment, animal testing center, clinical research center, and medical collaborative transformation center, providing essential hardware support for disease diagnosis and treatment [2] Group 2: Research Focus and Achievements - The institute has laid out specialized research areas including metabolism, neurology, cardiovascular health, and reproductive health, with a strong emphasis on returning research outcomes to patient care [3] - Notable achievements include a project on stem cell therapy for premature ovarian failure, which has been implemented in Hainan, and an innovative tumor vaccine developed from newly identified clinical targets, providing new treatment options for solid tumor patients [3] Group 3: Future Aspirations - The institute aims to integrate more resources with the support of provincial and municipal policies to enhance public health and contribute significantly to the local biomedicine industry [3]

Core Insights - A recent clinical study led by Professor Shao Zhimin from Fudan University Shanghai Cancer Center published in the British Medical Journal demonstrates a significant improvement in the treatment of high-risk early-stage triple-negative breast cancer (TNBC) patients through the addition of carboplatin to standard chemotherapy, achieving a 3-year disease-free survival rate of 92.3% and reducing recurrence risk by 36% compared to the control group [4][11]. Group 1: Clinical Study Overview - The study involved 808 high-risk early-stage TNBC patients, randomized into a trial group receiving intensified chemotherapy with carboplatin and a control group receiving standard treatment [10]. - High-risk patients were defined as those with lymph node metastasis or a high tumor cell proliferation index (Ki-67≥50%) [6]. Group 2: Treatment Efficacy - The trial group showed a 3-year disease-free survival rate of 92.3%, compared to 85.8% in the control group, representing a 6.5 percentage point absolute increase [11]. - The overall survival rate for the trial group reached 98.0%, indicating a significant advantage in key efficacy metrics [11]. Group 3: Safety and Side Effects - While the trial group experienced a slight increase in hematological toxicities such as neutropenia and anemia, these side effects were within expected ranges and deemed manageable [11]. - The study's findings support the safety and feasibility of the carboplatin-enhanced treatment regimen, laying a solid foundation for clinical application [11]. Group 4: Implications for Future Treatment - This research marks a shift from homogeneous chemotherapy to risk-based intensified treatment for early-stage TNBC, symbolizing a new era in precision medicine [12]. - The findings suggest a transition in standard treatment protocols from the current "anthracycline + taxane" regimen to a new combination including "anthracycline + taxane + platinum" [12].

Core Viewpoint - The publication of "Analysis of Typical Difficult Liver Disease Cases" by Professor Tan Youwen marks a significant shift from general public education to clinical practice, providing a comprehensive analysis of challenging liver disease cases for healthcare professionals [1][5]. Group 1: Book Overview - The book systematically covers seven core categories of liver diseases, including viral, fatty, drug-induced, autoimmune, vascular, genetic, and tumor-related diseases, featuring nearly a hundred selected difficult cases, with almost half previously published in academic journals [5]. - It emphasizes the importance of integrating various diagnostic information, such as laboratory tests, imaging, pathology, and genetic testing, to enhance precision in diagnosis and treatment [5][12]. Group 2: Author's Credentials - Professor Tan Youwen is a medical doctor and chief physician with over 30 years of experience in diagnosing and treating difficult liver diseases, recognized as a leading talent in Jiangsu Province [7]. - He has received more than ten provincial and municipal research awards and has published over 30 SCI papers, contributing to national educational materials [7]. Group 3: Case Studies Highlighted - The book includes notable case studies, such as the discovery of liver damage linked to a health supplement known as "God Fruit," which prompted a reevaluation of its safety in the medical community [8]. - Another case involved a 9-year-old girl diagnosed with progressive familial intrahepatic cholestasis through genetic testing, marking the first identification of a specific mutation in the Greater China region [9]. - A case of a patient initially diagnosed with alcoholic liver cirrhosis was later confirmed to have Wilson's disease, demonstrating the need for thorough investigation in seemingly typical cases [11]. Group 4: Academic Value - The book serves as a practical guide for physicians navigating the complexities of liver disease in the era of precision medicine, reflecting Professor Tan's three decades of clinical experience and wisdom [12].

Core Insights - Obesity is a significant global public health issue, with a retrospective study revealing that 69.5% of patients who underwent sleeve gastrectomy (SG) experienced weight regain, with over 40% meeting the medical criteria for "weight regain" [6][7][8] - The study identified the third year post-surgery as a critical period for weight rebound, providing data to help identify high-risk patients and develop preventive strategies [6][8] Summary by Sections Study Overview - A retrospective cohort analysis included 676 patients who underwent SG at Shanghai Jiao Tong University from January 2011 to June 2022, with a median follow-up of 3 years [6][7] - The study aimed to analyze long-term weight changes post-SG and identify factors influencing weight loss [6] Key Findings - The study found that baseline age, initial BMI, male gender, and absence of hypertension were associated with higher percentage of total weight loss (%TWL) post-surgery [7] - The lowest weight for most patients occurred within the first year post-surgery, followed by a significant weight regain in 69.5% of patients, peaking in the third year [7] - Among 540 patients with complete follow-up, the rate of weight regain increased from 21.7% at year 3 to 32.6% at year 5 [7] Weight Change Patterns - Patients who did not experience weight regain were categorized into three groups based on weight change trajectories: significant weight loss, moderate weight loss, and minimal weight loss [7] - The significant weight loss group had higher baseline BMI, waist circumference, fasting insulin, and insulin resistance index (HOMA-IR) compared to the minimal weight loss group [7]

Core Viewpoint - Chronic kidney disease (CKD) is a significant and worsening non-communicable disease globally, affecting 8%-14% of adults, leading to increased risks of end-stage kidney disease (ESKD) and cardiovascular events [1][2] Group 1: Disease Impact and Statistics - CKD patients face a significantly increased risk of ESKD and major cardiovascular events, resulting in approximately 2.6 million deaths annually, with 960,000 deaths attributed to ESKD [1] - Hyperuricemia is a common and modifiable complication in CKD patients, with a prevalence twice that of the general population, and its incidence rises sharply with the progression of kidney disease [1][4] Group 2: Research Findings - A recent multicenter real-world study published in "Signal Transduction and Targeted Therapy" demonstrated that urate-lowering therapy (ULT) significantly reduces the risk of kidney function loss and all-cause mortality in CKD patients with hyperuricemia, regardless of gout attacks [2][4] - The study included 269,831 eligible participants, with a primary outcome of composite kidney outcomes defined by a decline in estimated glomerular filtration rate (eGFR) of over 40% or ESKD [5] Group 3: Treatment Outcomes - The cumulative incidence of composite kidney outcomes over three years was 19.69% in the ULT group compared to 23.22% in the control group, indicating a risk difference of -3.53% [5] - The estimated risk differences for ESKD, all-cause mortality, and cardiovascular mortality over three years were -1.88%, -2.25%, and -0.69%, respectively, all favoring the ULT group [5][7]

Core Viewpoint - The article discusses the development of a multimodal AI model named eSPARK, which aims to enhance personalized treatment decisions for esophageal cancer, particularly esophageal squamous cell carcinoma (ESCC) [4][9]. Group 1: Background and Importance - Esophageal cancer (EC) is a common malignant tumor and the seventh leading cause of cancer-related deaths, with ESCC accounting for approximately 80% of cases [2]. - The prognosis for ESCC is poor, primarily due to late-stage diagnosis, and traditional surgical interventions have limited effectiveness for advanced cases [2][3]. Group 2: New Treatment Approaches - Neoadjuvant immunochemotherapy (nICT) has emerged as a promising treatment for esophageal cancer, but it only achieves optimal results in 20%-40% of patients, highlighting the need for reliable biomarkers to predict treatment response [3][6]. - The urgency to identify biomarkers is driven by the potential for improving patient outcomes and reducing unnecessary toxic side effects associated with over-treatment [3]. Group 3: Research Development - The study published in Cell Reports Medicine introduces the eSPARK model, which integrates multimodal deep learning to enhance predictive performance for nICT efficacy in ESCC [4][6]. - The model utilizes data from 344 patients, incorporating pre-treatment CT images and pathology slides, along with post-operative pathological complete response (pCR) outcomes [7]. Group 4: Key Findings - eSPARK demonstrates superior generalization capabilities compared to unimodal models and achieves robust predictive accuracy across multicenter datasets [7]. - The model identifies several biomarkers related to nICT treatment response, including the neutrophil-to-lymphocyte ratio (NLR), where a lower NLR may indicate better treatment response [7][9]. - The research emphasizes the potential of eSPARK in personalized treatment decision-making for locally advanced esophageal cancer and its broader implications for precision oncology through multidisciplinary data integration [9].

Core Viewpoint - Tsinghua University’s Beijing Tsinghua Changgung Hospital has launched a clinical medicine technology innovation platform to enhance collaboration in clinical research and development, aiming to address key challenges in clinical medicine and accelerate the transition of new technologies to clinical applications [1][2] Group 1: Platform Launch and Structure - The newly established platform integrates six core entities: Clinical Biobank Resource Center, Clinical Drug and Device Testing Center, Clinical Translational Medicine Center, Medical Data Science Center, Health Technology R&D Center, and Clinical Research Center [1] - This platform aims to create a collaborative innovation system that covers the entire chain from clinical research to clinical validation, facilitating resource sharing and capability enhancement among the entities [1] Group 2: Mission and Goals - The platform is designed to fulfill three main missions: to build a collaborative innovation hub, to cultivate leading teams in medical-engineering integration, and to drive the application of smart healthcare technologies [1] - The focus is on accelerating the transition of new technologies from the laboratory to clinical settings, ultimately benefiting public health with innovative outcomes [1] Group 3: Collaborative Initiatives - Tsinghua Changgung Hospital has initiated a comprehensive research alliance to share resources and conduct high-level clinical research in collaboration with multiple medical institutions [2] - Strategic partnerships have been established with Tsinghua University’s Biomedical Engineering Department and the National Key Laboratory of Membrane Biology, enhancing the research capabilities [2] Group 4: Innovation Outcomes - The conference showcased significant innovations, including the launch of the "Qingxin" ECG model and the "AI Liver and Gallbladder Super Doctor" intelligent system, demonstrating the effectiveness of medical-academic and medical-enterprise collaborations [2] - The event featured a keynote report by academic leaders discussing the evolving role of doctors in the AI era, emphasizing the need for improved clinical decision-making and integration of medical-engineering practices [2]

12月8日，国内首个脑转移瘤精准放疗IIT研究，首都医科大学宣武医院ZAP-X IIT研究启动仪式顺利召 开。该临床研究(Investigator Initiated Trial，简称IIT)由宣武医院与百洋医药（301015.SZ）合作开展，宣 武医院神经外科主任张鸿祺担任主要研究者（PI），旨在进一步探索全球领先的脑肿瘤精准放疗设备 ——ZAP-X放射外科机器人在脑转移瘤患者中的临床疗效与安全性、剂量学特征。 ...

Core Insights - Breast cancer is the most prevalent cancer among women globally, with nearly 70% of patients diagnosed with luminal-type breast cancer [1] - Chinese medical experts have utilized an AI model to identify precise treatment targets for immune-regulatory and RTK-driven luminal-type breast cancer patients, significantly improving treatment efficacy [1] Group 1: Research Findings - The research led by Professor Shao Zhimin was published in the renowned journal "Cancer Cell" and categorized luminal-type breast cancer into four subtypes: classic luminal (SNF1), immune-regulatory (SNF2), proliferative (SNF3), and RTK-driven (SNF4) [1] - The study, named LINUX, is a multi-center, randomized, controlled Phase II clinical trial focusing on treatment challenges for advanced luminal-type breast cancer patients who have developed resistance [1] Group 2: AI Model Application - The AI molecular model, described as a "super brain," integrates vast amounts of microscopic information and can produce molecular typing results within five minutes, significantly lowering the barriers and costs for precision diagnosis [2] - The clinical research demonstrated that for immune-regulatory and RTK-driven luminal-type breast cancer patients, different precision treatment strategies increased objective response rates from 30% to 65% and from 20% to 70%, respectively, with median progression-free survival more than doubling for both subtypes [2] Group 3: Future Plans - The research team plans to conduct a multi-center, randomized controlled Phase III clinical trial targeting precision treatment strategies for immune-regulatory (SNF2) and RTK-driven (SNF4) patients to validate their effectiveness and superiority in a larger patient population [2]

Core Insights - The "Health China 2030" plan highlights diabetes as a key chronic disease for prevention and treatment, with Diabetic Macular Edema (DME) identified as a significant challenge in eye disease management [1][4] - A new research initiative, the "DME Disease Diagnosis and Treatment Insight Research Project," will be launched on World Diabetes Day 2025 to analyze the current treatment landscape for DME in China [1][4] Group 1: Project Overview - The project aims to shift the treatment paradigm for DME from short-term fluid control to long-term disease management, focusing on recurrence risk and treatment expectations [4] - The initiative will involve a nationwide survey targeting over a thousand doctors from tertiary and secondary hospitals, collecting data on DME recurrence risk factors and long-term treatment needs [4][5] Group 2: Goals and Methodology - The project will utilize standardized questionnaires to gather insights from clinical practices, aiming to enhance communication between doctors and patients and develop more effective treatment pathways [4][5] - A comprehensive "DME Disease Diagnosis and Treatment Research White Paper" will be produced, disseminating findings to raise awareness about long-term management strategies for DME [5]